Dendritic cells (DC) are professional antigen-presenting cells capable of initiating a potent primary immune response, making them an attractive target for cancer immunotherapy. Flt-3 ligand (Flt-3L) is a haematopoietic growth factor that efficiently induces DC expansion in vivo. To achieve a more efficient and effective method of priming tumour-specific, DC-mediated immune response, we generated a DNA vaccine comprising both human Flt-3L and the tumour antigen, MUC-1 (pNGVL-hFLex-MUC-1). We report that pNGVL-hFLex-MUC-1 is able to induce antigen-specific CTL immunity in vivo, resulting in a potent anti-tumour response, and that the Flt-3L component is essential to the efficacy of the DNA vaccine. Moreover, the route of immunization is critical in determining the type of immune response generated; intramuscular (i.m.) immunization with pNGVL-hFLex-MUC-1 conferred tumour protection in contrast to poor response with hydrodynamic-based intravenous delivery. Post-i.m. immunization, we observed a massive infiltration of mononuclear cells to the injection site, comprised predominantly of CD11c
Introduction
Dendritic cells (DC) are the primary antigen-presenting cells (APC) of the immune system. They are able to efficiently internalize, process and present antigen, stimulating both naive and memory T cells. 1 This unique ability of DC to stimulate the primary immune response places them as a logical target for cancer immunotherapy. DC loaded with tumour-associated antigen ex vivo have been demonstrated to induce antigen-specific immune response in vitro and in animal models. To date, use of DC-based immunotherapy have proven promising in human clinical trials treating certain types of malignancies, providing proof-of-concept that DC, presenting tumour antigens, are able to elicit clinically relevant antitumour response. 2 However, DC occur at a very low frequency in most tissues, and although relatively large numbers of DC can be obtained through ex vivo propagation of DC progenitors, the process is labour intensive, complex and far from ideal. 2 It would therefore be more advantageous to manipulate DC in vivo.
The ligand for the fms-like tyrosine kinase 3 (Flt-3L) is a pluripotent haematopoietic growth factor. 3, 4 Human Flt-3L has been shown to induce DC expansion in mice and humans, 5 and also enhance DC-mediated immunogenicity in mouse models. 6, 7 Although no tumour specificity could be demonstrated, it has been reported that following treatment with human Flt-3L, there is a marked recruitment of DC to the tumour site. 7, 8 In addition, human Flt-3L increases DC numbers across the DC subsets, 3 and in lymphoid and nonlymphoid organs. 9, 10 Genetic immunization using naked DNA is an attractive approach to vaccinate against tumour-associated antigens in cancer immunotherapy. It offers several advantages over peptide-based vaccination; (1) duration of expression of the peptide antigen in peptidepulsed DC is restricted by its half-life; (2) antigen introduced as a transgene can be cross presented on MHC Class I and Class II to initiate both cellular and humoral immune responses; (3) DNA is temperature stable, allowing ease of transport and storage, in addition to the availability of rapid and large scale DNA preparation, which would greatly simplify the vaccine development and production process.
Direct injection of naked plasmid DNA induces a strong, long-lived immune response to the encoded antigen. 11 An important advantage of DNA vaccination is the potential continuous expression of the introduced antigens in environments containing APC, thereby promoting a long-lasting and efficient therapeutic immune response. Moreover, as tumour cells undergo a high rate of mutation that could result in the loss of expression of antigenic epitopes, peptide-based immunotherapy, consisting of a single tumour-associated epitope, would not be able to provide a long-term and effective tumour-specific immune response. In comparison, DNA vaccines encoding several antigens or proteins can be delivered to the host in a single dose. Such protocols have been successfully employed against infectious diseases caused by agents such as viruses, bacteria and parasites. 12, 13 The method and route of DNA delivery also influences the immune response generated. Although several methods have been developed to deliver DNA vaccines, 11, 14, 15 intramuscular (i.m.) inoculation via direct needle injection of plasmid DNA has been shown to induce long-lasting, antigen-specific humoral and cellular response. [16] [17] [18] [19] Recently, we demonstrated that systemic administration of a peptide vaccine, MUC-1, in combination with in vivo expansion of DC via immunization with human Flt-3L, induced a MUC-1-specific cellular response resulting in the retardation of tumour growth in recipient mice, 20 but not complete regression. In order to enable a more potent cellular immunity, we generated a DNA vaccine encoding a fusion protein comprising human Flt-3L and MUC-1. We report here that the chimeric DNA vaccine is sufficient in itself to induce antigen-specific CTL immunity in vivo, resulting in the regression of tumour in the recipient mice, and that the efficacy of the vaccine is dependent on the route of immunization. Therefore, this protocol could potentially be employed in developing gene-based therapies for human malignancies.
Results
Generation and in vitro expression of pNGVL-hFLex-MUC-1 DNA construct A DNA construct, pNGVL-hFLex-MUC-1, was generated encoding the extracellular domain of human Flt-3 ligand (FL) ligated in frame to the tumour epitope MUC-1, under the control of the CMV promoter (Figure 1a) , so as to express a fusion protein, which exhibits dual functionality, cognizant of its respective components. The Flt-3L is a known potent inducer of DC expansion in vivo, and it is postulated that the secreted chimeric protein will enable the presentation of the MUC-1 epitope to the expanded DC population to efficiently generate MUC-1-loaded DC. Constructs containing FL only or MUC-1 only or empty vector were used as controls in this study ( Figure 1a) .
To confirm that the fusion protein can be expressed, we transfected A549 cells with pNGVL-hFLex-MUC-1, and stained with antibodies against FL (red) and MUC-1 (green). The construct transfected efficiently, and as shown in Figure 1b , both FL and MUC-1 proteins coexpressed at high levels in the cytoplasm. In addition, expression was detected by Western blot analysis of total cell lysate from transfected A549 cells, with either a polyclonal antibody against FL or a monoclonal against MUC-1 (Figure 1c) . Consistent with the immunofluorescence data, FL and MUC-1 proteins are highly expressed in A549 cells transfected with pNGVLhFLex-MUC-1. As expected, the fusion protein resolves at a higher molecular weight corresponding to the combined sizes of FL and MUC-1. Therefore, we have established that the pNGVL-hFLex-MUC-1 construct is able to efficiently express both components as a fusion protein.
In addition, to confirm that the control constructs are viable, we transfected A549 cells with pNGVL-MUC-1. MUC-1 expression was detected by confocal microscopy Flt-3L-MUC-1 DNA vaccine induces tumour immunity CL Fong et al ( Figure 1d ). pNGVL-hFLex expression has previously been shown. 20 Hydrodynamic-based intravenous (i.v.) immunization of pNGVL-hFLex-MUC-1 induces expansion of CD11c + DC in vivo
We previously reported that using pNGVL-hFLex, the hydrodynamic-based i.v. route of immunization induces the expansion of DC, which with subsequent i.v. presentation of tumour antigen peptide resulted in a marked antitumour response. 20 Therefore, we utilized the same route of immunization for the pNGVL-hFLex-MUC-1 genetic vaccine, using C57BL/6 mice. The fusion protein secreted into the bloodstream would mimic the i.v. delivery of human Flt-3L and MUC-1 peptide simultaneously. The expanded DC population, induced by the Flt-3L component, would then be able to take up the MUC-1 antigen. The amount of fusion protein in the blood was determined by ELISA, using an antibody against FL. At the DNA vaccine concentration of 10 mg, maximal protein expression was obtained, and the levels of FL protein detected in mice injected with pNGVL-hFLex-MUC-1 was comparable to control mice injected with pNGVL-hFLex ( Figure 2a ). The expression of FL-MUC-1 protein peaks at day 1 to day 2, with a concentration of 50-70 mg/ml, and progressively decreases over time, although the fusion protein could still be detected in the blood 40 days postinjection, at approximately 2-8 ng/ml (data not shown).
The Flt-3L is a potent inducer of DC expansion. 3, 10 Mice were inoculated with pNGVL-hFLex-MUC-1, pNGVL-hFLex or empty vector by hydrodynamic-based i.v. tail vein injection, and splenocytes analysed at various time points to determine the changes in DC population. Inoculation with either FL-derived plasmid DNA resulted in increased cellularity of the spleen as shown in Table 1 . Total T-cell numbers (CD3 + CD8 + and CD3 + CD4 + ) remained constant after DNA immunization. However, there is a significant increase in CD11c + cells, suggesting that the increased splenic cellularity is primarily due to DC expansion, and different DC subsets are shown to be upregulated, indicating a general expansion of DC subtypes. There is also an increase in CD19 + B cells, which has been reported previously. 9 However, there is no significant difference in the relative proportion of CD11c + /ClassII + splenic cells derived from pNGVL-hFLex-and pNGVL-hFLex-MUC-1-immunized mice (Figure 2b ). We then analysed the kinetics of DC induction by determining the percentage of CD11c + / ClassII + cells in the spleen over time. As seen in Figure  2c , from day 4 to day 6, there was a 20% increase in CD11c + /ClassII + DC in mice immunized with either pNGVL-hFLex-MUC-1 or pNGVL-hFLex, which was sustained to day 10, followed by a gradual decrease. Therefore, addition of the MUC-1 peptide epitope to the DNA construct did not appear to impair the ability of the FL component to induce DC expansion.
In addition to the spleen, we demonstrated that Flt-3L is able to induce CD11c + /ClassII + DC expansion in other lymphoid and nonlymphoid organs, which are traditional sites of DC activity (Figure 2d) . The DC population peaks on the same day in all the organs examined, suggesting a systemic effect by Flt-3 ligand when administered intravenously.
DC generated by i.v. immunization are immune competent but fail to induce an antitumour response Having demonstrated that the chimeric DNA vaccine pNGVL-hFLex-MUC-1 is able to expand DC in vivo, we then investigated whether this induced population is able to act as APC in situ, and present antigen introduced via genetic immunization. Mice were first inoculated with pNGVL-hFLex to generate an initial expansion of the DC population. This was done as protein expression from plasmid DNA in the blood decreases to 1.5% (Figure 2a ) by day 7, which is the length of time required for DC expansion to peak. 20, 21 At 10-day intervals, we administered a second and third immunization with pNGVL-hFLex-MUC-1 via i.v. injection. At 10 days postthird immunization, the splenocytes were harvested, restimulated with MUC-1 peptide in vitro, and assayed for anti-MUC-1-specific secondary CTL activity using RMA-MUC-1 tumour cells as target. As shown in Figure  3a , there is significant CTL activity exhibited by splenocytes from mice primed with pNGVL-hFLex-MUC-1. IFN-g production is correlated with a Th1 response, which drives the propagation of effector CTL. We show here that likewise, IFN-g was detected only in the culture supernatant derived from pNGVL-hFLex-MUC-1-immunized mice (Figure 3b ). In addition, weak, but statistically significant level of anti-MUC-1 antibodies were also detected in mice immunized with pNGVL-hFLex-MUC-1 (Figure 3c) .
In comparison to our previous study using a DNA and peptide combined vaccine, 20 the pNGVL-hFLex-MUC-1 genetic vaccine is similarly able to generate antigenloaded DC capable of priming a CTL response. Therefore, we speculate that this DNA vaccine may also provide antitumour protection in vivo.
This was investigated using an experimental tumour model, whereby mice were initially inoculated with pNGVL-hFLex to augment the DC population and subsequently immunized twice with pNGVL-hFLex-MUC-1 by i.v. injection. At 10 days following the last immunization, the mice were challenged with a lethal dose of 5 Â 10 5 RMA-MUC-1 cells injected subcutaneously ( Figure 3d ). However, there was no detectable protection against the aggressive proliferation of the RMA-MUC-1 tumour cells. This is in marked contrast to our previous report, whereby MUC-1 peptide-pulsed pNGVL-hFLex-induced DC generated a significant antitumour response. 20 Although we are uncertain as to the underlying mechanism responsible for this difference, it has been reported that the route of immunization is critical in establishing the appropriate immune response. It was shown that DNA immunization via the i.m. route elicits a sustained CTL and antibody response 16 and in particular, i.m. inoculation with a secreted antigen generates a strong Th1 response. It is most likely that the amount of protein secreted is less than 10 pg/ml, below the threshold of detection for ELISA. However, transgenic protein could be detected in the muscle tissue around the site of injection on day 1 postimmunization at 0.2 pg fusion protein per mg muscle tissue ( Figure 4a ). This suggests that plasmid DNA, when inoculated intramuscularly, is expressed locally at the site of inoculation. Correlating with the lack of transgenic Flt-3L in the blood, there was no detectable expansion of DC population in the spleen (data not shown).
In spite of poor systemic response to the Flt-3L component, we harvested splenocytes from immunized mice and assayed for MUC-1-specific CTL activity. Injection of DNA into muscle has previously been reported to result in transient infiltration by immune cells, and hence, although muscle does not contain significant numbers of APC, additional cells could be recruited to salvage antigens from the transduced muscle cells. 22, 23 Mice were immunized with pNGVL-hFLex-MUC-1 and as shown in Figure 4b and c, there is significant anti-MUC-1-specific secondary CTL activity exhibited by both the purified splenocytes and superficial inguinal lymph node cells stimulated in vitro with synthetic MUC-1 peptide. Mice were also intravenously inoculated with pNGVL-hFLex to stimulate systemic DC expansion prior to pNGVL-hFLex-MUC-1 i.m. immuni- Flt-3L-MUC-1 DNA vaccine induces tumour immunity CL Fong et al zation to enhance the immune response. However, the CTLp frequency obtained under either protocol was comparable (Table 2 ). This implies that pNGVL-hFLex-MUC-1 introduced intramuscularly does not require systemic DC expansion to generate a potent CTL response. However, i.m. vaccination of pNGVL-MUC-1 was not able to generate a significant immune response and mice immunized with pNGVL-hFLex-MUC-1 showed higher CTLp frequency (average CTLp of 1/ 60100) as compared to pNGVL-MUC-1-inoculated mice (average CTLp of 1/447500) ( Table 2 ). This suggests that the Flt-3L component is critical for vaccine efficacy. The presence of active CTL was further supported by the detection of IFN-g in the culture supernatant (Figure 4d ). Comparable levels of IFN-g were produced in corresponding samples that exhibited CTL activity. However, there was no significant antibody response in mice immunized intramuscularly with pNGVL-hFLex-MUC-1 (data not shown).
The significant effector CTL activity suggested a promising antitumour response. Therefore, mice were immunized intramuscularly 3 Â with pNGVL-hFLex-MUC-1 alone or with prior pNGVL-hFLex-induced DC augmentation. Control cohorts were inoculated with pNGVL-hFLex or pNGVL-MUC-1. Following vaccine administration, mice were challenged with a lethal dose of RMA-MUC-1 tumour cells, injected subcutaneously. Figure 5a presents tumour size following the immunization regimes and demonstrates conclusively tumour regression in mice immunized with pNGVL-hFLex-MUC-1. In Figure 5b , we show that the antitumour response was MUC-1-specific as the control tumour, induced by parental RMA tumour cells, progressed aggressively. Systemic DC expansion prior to pNGVLhFLex-MUC-1 vaccination did not appear to provide an advantage for tumour protection (Figure 5c ). In comparison, inoculation of pNGVL-MUC-1, with or without DC augmentation, did not confer any protection (Figure 5d ). This suggests that in our system, Flt-3L possibly acts as an adjuvant to enable MUC-1 processing and presentation by APC to generate an efficient immune response, and that i.m. route of immunization is preferential when presenting a genetic epitope.
DC are recruited to i.m. immunization sites by pNGVL-hFLex-MUC-1
Injection of DNA into muscle has been reported to result in transient infiltration by immune cells. 22, 23 However, inoculation of pNGVL-MUC-1 did not elicit an immune response. Therefore, to investigate the adjuvant activity of the Flt-3L component in enhancing the efficacy of pNGVL-hFLex-MUC-1, muscle tissues adjacent to the inoculation sites were harvested. Figure 6a shows muscle sections derived from pNGVL-hFLex-MUC-1-and pNGVL-MUC-1-inoculated mice, and stained with haematoxylin. Inoculation with pNGVL-hFLex-MUC-1 resulted in massive infiltration of mononuclear cells into the muscle (right panel). In contrast, inoculation with pNGVL-MUC-1 resulted in a comparatively lower influx (left panel). Immunohistochemical studies revealed specific cell types recruited to the immunization sites. Muscle sections derived from pNGVL-hFLex-MUC-1-inoculated mice were stained with a panel of antibodies as shown in Figure 6b . High numbers of CD11c + DC were identified within the mononuclear cell infiltrate (Figure 6b ). However, there were no CD3 + cells detected (Figure 6b) , indicating the absence of T cells. In addition, no CD8a + cells could be observed, suggesting that the recruited DC were of the CD11c + /CD8a À subtype. It has been reported that Flt-3L-induced DC recruitment to the inoculation site correlates with enhanced T-cell immunity. 24 Therefore, the efficacy of pNGVL-hFLex-MUC-1 could be attributed to the ability of the Flt-3L component to increase recruitment of DC to the immunization site, where the secreted FL-MUC-1 fusion protein can be internalized and eventually crosspresented. Nevertheless, we cannot rule out the possible involvement of other APC, such as macrophages, within the cell infiltrate in eliciting an immune response. It is of interest that prior DC stimulation did not significantly enhance the specific immune response, suggesting that local recruitment of DC and possibly other APC, but not systemic expansion of DC, is crucial in determining the efficiency of i.m.-inoculated DNA vaccines.
Discussion
The efficacy of a vaccine depends largely on the nature of the antigen and the route of immunization used, as these two factors significantly affect the type of immune 
Day (d) 12 Flt-3L-MUC-1 DNA vaccine induces tumour immunity CL Fong et al response generated. Ideally, there should be induction of both humoral and cellular immunity, which would prime the host defence against foreign pathogens or malignant cells. DC play a central role in the immune response engendered by DNA immunization. 11 These cells express high levels of MHC and costimulatory molecules, in addition to secreting a wide array of immunoregulatory cytokines, and most importantly, they take up and process antigen in peripheral blood and tissue, subsequently migrating to the lymph nodes where they present antigen to resting lymphocytes. Therefore, one may envisage priming host DC with tumour-associated antigens as an attractive route for cancer immunotherapy.
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The mucin family has emerged as a potential therapeutic target in cancers of the breast, colon, pancreas, lung and ovary. 25 Mucin molecules, such as MUC-1, are large transmembrane glycoproteins that act as immunodominant epitopes to elicit T-and B-cell immunity, due in part to the differences between normally expressed MUC-1 and the tumour-associated form. MUC-1 is normally a highly O-glycosylated glycoprotein, comprising tandem repeats of the mucin domain, each with five O-glyscosylation sites. The extracellular region of the protein consists of a variable number of tandem repeats (VNTR) of the 20 amino-acid sequence (GVTSAPDTRPAPGSTAPPAH), extensively O-glyscosylated at the threonine and serine residues with complex sugars. MUC-1 was first identified on the luminal surface of epithelial cells, but has also recently been found at low levels on cells of haematopoietic origin. In normal breast epithelial cells, the extracellular domain is densely covered with highly branched complex carbohydrate structures. However, the expression of MUC-1 is elevated in many forms of epithelial cancers, and, as a consequence, is hypoglycosylated with sparse distribution of carbohydrate structures, resulting in an autoantigen. The reduced level of glycosylation is believed to result in the exposure of a highly immunogenic core peptide sequence PDTRP, as well as the normally cryptic Tn (GalNAc), STn (sialyl alpha2-6 GalNAc) and TF (Gal beta1-3 GalNAc) carbohydrates. 25 There have been many different clinical trials in recent years to assess the ability of MUC-1-based vaccines to generate strong cytotoxic anti-MUC-1-specific responses against solid MUC-1-expressing tumours. However, for the MUC-1-based vaccines to generate an effective response, it is crucial to employ vaccine candidates that are representative of the structure, dynamics, epitope exposure and the glycosylation state of the tumourassociated mucin. We previously demonstrated that i.v. inoculation with pNGVL-hFLex induced a systemic expansion of DC, and on subsequent i.v. introduction of MUC-1 peptide, generated MUC-1-specific CTL response.
To enable a more efficient approach, we designed a DNA vector that encodes both human Flt-3L and MUC-1 on the same plasmid. The MUC-1 antigenic epitope encoded by pNGVL-hFLex-MUC-1 is a 30 mer that falls within the VNTR region of the MUC-1 molecule and contains two copies of the antigenic epitope PDTRP. This strategy offers several advantages over the previous peptide vaccine. Plasmid DNA is relatively stable and easy to generate, and is cost-effective. There is prolonged expression of antigen, and the antigen source is more resistant to antibody-mediated clearance. By fusing the MUC-1 antigen to a secretory DC-related protein, it is postulated that transduced cells will express and secrete the MUC-1 fusion protein, thereby allowing uptake by DC, which will then process and present the antigen to lymphocytes. In addition to presenting antigen in association with MHC Class II, DC have the unique ability to translocate exogenous antigen, internalized by various pathways, to MHC Class I presentation. 26, 27 Another advantage of DNA vaccines is that transduced cells, whether immunologic or somatic, are able to express the protein encoded, resulting in MHC Class I presentation.
We demonstrate that despite fusion with MUC-1 peptide, the efficacy of the human Flt-3L component to expand DC is not impaired. Expansion of DC in vivo circumvents complex procedures required to isolate and culture DC progenitors in vitro before reintroducing the cells back into the host. Human Flt-3L has also been shown to expand multiple subsets of DC and in different organs, which is ideal for immunotherapeutic purposes to obtain an optimal response. 5, 10 Our approach is based on the assumption that expansion of DC in situ will enhance antigen presentation and subsequently increase the ability of the immunized host immune system to respond to exogenous peptide. As previously reported, a single inoculation of human Flt-3L is able to expand DC populations in vivo by 20% in 7 days. 20 Subsequent i.v. inoculation with pNGVL-hFLex-MUC-1 produced anti-MUC-1-specific CTL, correlating with an increase in IFNg production. This implies that genetic immunization of DNA-encoded tumour antigen is able to generate a Th1 Flt-3L-MUC-1 DNA vaccine induces tumour immunity CL Fong et al response, which is mediated by DC. However, despite the induction of MUC-1-specific immunoreactivity, there was no protection upon challenge with RMA-MUC-1 tumour cells. It is unclear as to why that is so. One possibility is that the immune response generated was insufficient (average CTLp of 1/447 500) to halt the aggressive proliferation of the tumour cells. It is also likely that the timing of the immunizations is critical and the protocol used may not be optimal. Although it is conventional for peptide vaccines to be delivered intravenously, it has been reported that naked DNA is more efficiently administered intramuscularly or intradermally. 28 In this study, we report that mice immunized intramuscularly with pNGVL-hFLex-MUC-1 produced high levels of MUC-1-specific CTL and IFN-g, and that this response is sufficient to confer protection against RMA-MUC-1-induced tumours. In addition, the MUC-1-specific CTL were able to initiate an immune response against synthetic, nonglycosylated MUC-1 peptide, suggesting the potential application of our immunotherapeutic approach for human cancers with hypoglycosylatyed MUC-1 epitope. This protection occurs in spite of the lack of transgenic protein secreted into blood sera. Within the muscle tissue, APC are sparse, and though they may be recruited to the injection site, it is unlikely that sufficient numbers of APC will be transfected. It has been demonstrated that muscle cells are able to express a foreign protein for a significant period of time following direct in vivo gene transfer, 29 resulting in the induction of potent cellular and humoral immune response. 11 Length of time of expression depends on cellular localization of the protein. Secreted proteins are expressed for a shorter period of time, approximately 20 days, 30 although it has been demonstrated that secreted protein was the most effective in stimulating both CTL and humoral responses, whereas cytoplasmic protein failed to induce any immune response. 18 However, it has been reported that presentation of antigen by somatic cells, which lack costimulatory molecules, are more likely to induce tolerance. 31 A number of investigators have addressed this question by showing that the initiation of the immune response following DNA immunization into muscle is dependent on the recruitment of bone-marrow derived APC such as DC, which then traffic to draining lymph nodes with the processed antigen, 19 ,32 which supports our observation that cells harvested from the draining lymph nodes exhibited significant cytolytic activity against MUC-1 target cells (Figure 4c) . Moreover, it has been shown that under certain conditions, protein can be transferred from somatic cells to APC for presentation. [33] [34] [35] [36] It has also been reported that the induction of cytototxic T lymphocytes could enhance the humoral response following DNA immunization. 37 Therefore, these observations suggest the possible mechanism through which immunity was generated against the MUC-1 epitope.
An alternative to i.m. immunization, nucleic acid immunization via the skin could also potentially result in an efficient immune response by introducing DNA in a variety of cells including keratinocytes, Langerhans cells and DC. Many dermal immunization methods that target the epidermis, the dermis or both, have been described and include stripping, chemical modification, trans-epidermal immunization (trans-cutaneous immunization or noninvasive vaccination of the skin), gene gun technology, electroporation, intradermal injections and microseeding. 38 However, differences in DNA vaccine delivery strategies could elicit distinct immune responses and have significant effects on the outcome of immunization as demonstrated in a study by Boyle et al. 39 where intradermal delivery of DNA generated a Th2-type response in contrast to i.m. delivery which resulted in Th1-type reponse.
As it has been reported that DC recruitment to muscle tissue is crucial, we postulated that augmenting the systemic DC population prior to DNA immunization would enhance the immune response. However, there was no observable significant advantage in this study. One possible explanation is that, for DC-induced CTL response, DC numbers are of minor importance once the minimal threshold for effective DC-CTL interaction has been reached. 40 The main function of the human Flt-3L component was to expand and recruit DC in situ and we have shown that this function is critical for the efficacy of the DNA vaccine, as inoculation with pNGVL-MUC-1 intramuscularly failed to produce a significant immune response. Various cytokines and costimulatory molecules are known to act as molecular adjuvants. GM-CSF, an essential growth and differentiation factor for DC in vitro, has been shown to improve the effectiveness of DNA vaccines when coexpressed with antigen on the same plasmid, resulting in augmented antigen-specific tumour immunity. 41 Recently, there has been growing evidence that Flt-3L displays similar vaccine adjuvant activity. 24, 42 Therefore, we propose that, in our tumour model system, Flt-3L acts to enhance immunity against MUC-1 antigen, and it does this by increasing DC recruitment to the immunization site, as there is a marked infiltration of CD11c + cells. However, systemic expansion of DC prior to immunization did not further enhance the efficacy of pNGVL-hFLex-MUC-1. The mechanism underlying this difference remains elusive, although these observations suggest that DC expansion or recruitment in situ is a crucial parameter in improving DC-based immunotherapy. Similarly, a recent clinical study demonstrated that systemic expansion of DC prior to the administration of a peptide vaccine intradermally did not enhance vaccine efficacy. 43 The absence of DC recruitment to the immunization sites was implicated in the failure to induce T-cell immunity.
Therefore, our results suggest that coexpression of antigen and human Flt-3L in the same plasmid is a promising strategy to elicit a protective Th1 response of a sufficient magnitude to generate resistance against tumours. Furthermore, it is in situ, not systemic, expansion or recruitment of DC that enhances the efficacy of a DNA vaccine delivered intramuscularly. Undoubtedly, additional studies are needed to improve this strategy and eventually optimize the approach for clinical settings, allowing alternative DC-based immunotherapy for cancer.
Materials and methods

Animals and cell lines
Female C57BL/6 mice were purchased from the Animal Laboratory Unit of the National University of Singapore 
Peptides
The MUC-1 peptide used has the sequence PDTRPAPG STAPPAHGVTSAPDTRPAPGST and falls within the VNTR region of the MUC-1 molecule. 44 The control peptide, NP-Flu, is derived from NP 365-380 of the human influenza virus and has the sequence IASNENMET MESSTLE. 45 The peptides were synthesized and obtained from Mimotopes, Clayton Victoria, Australia. It was purified by HPLC and found to be 495% in purity.
Construction of pNGVL-hFLex-MUC-1 and pNGVL-MUC-1 DNA vaccines
The pNGVL-hFLex plasmid has been described previously. 46 The MUC-1 oligonucleotide(CCGGACACCA GGCCGGCCCCGGGCTCCACCGCCCCCCCAGCCCAT GGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCC GGGCTCCACCTAG) containing the NheI and BamH1 restriction sites was ligated in frame to the human Flt-3 gene to generate pNGVL-hFLex-MUC-1 46 ( Figure 1 ). To construct pNGVL-MUC-1 (Figure 1 ), MUC-1 DNA sequence was PCR-amplified from pNGVL-FLex-MUC-1, using a forward primer incorporating the kozak sequence and start codon (5 0 GCGTCGACGCCACCAT GCCGGACACCAGGCCGGCC 3 0 ) and reverse primer incorporating the stop codon (5 0 GCGGATCCCTAGGT GGAGCCCGGGGCCG GCCTGGT 3 0 ). The PCR product was first cloned into TOPO cloning vector (Invitrogen, CA, USA) and then into pNGVL vector.
In vitro transfection 1 Â 10 5 A549 cells were grown onto glass coverslips in 60 mm dishes. The cells were then transfected with pNGVL-hFLex, pNGVL-hFLex-muc1 or pNGVL-MUC-1, using Lipofectamine reagents (Invitrogen, CA, USA) prior to immunofluorescence staining and Western blot analysis.
Immunofluorescence staining
Transfected A549 cells were fixed with ice-cold methanol and washed with PBS before blocking with blocking buffer (1% BSA, 0.1% Triton-X 100, 10% normal goat serum and 0.02% sodium azide in TBS) for 1 h at room temperature (RT). Cells were stained with primary antibodies for 1 h at RT: rabbit anti-FL antibody (Chemicon, CA, USA) and mouse anti-MUC-1 antibody (BD Pharmingen, CA, USA) (final concentration 0.5 mg/ ml), followed by secondary AlexaFluor antibodies (Molecular Probes, USA). Excess antibody was removed and sample was analysed with a confocal microscope (Carl Zeiss, Germany).
Western blot
Transfected cells were lysed in Lysis Buffer (50 mM TrisHCl, 150 mM NaCl and 1% Triton-X 100) containing protease inhibitor mixtures (Roche, USA). Total cell lysate (50 mg/well) was separated on a 12% denaturing acrylamide gel, and blotted onto nitrocellulose membrane. Filters were washed and stained with mouse anti-MUC-1 antibody (0.5 mg/ml) (BD Pharmingen, CA, USA) or goat anti-Flt-3 polyclonal antibody (0.5 mg/ml) (Santa Cruz, CA, USA), followed by secondary antisera conjugated to HRP. Filters were developed using enhanced chemiluminescence (Pierce, IL, USA).
Gene delivery
In vivo delivery of plasmid DNA was performed using either hydrodynamic-based tail vein injection,. 47 or direct needle i.m. injection. For hydrodynamic-based tail vein injection, 10 or 20 mg of plasmid DNA was diluted in 2 ml of sterilized 0.9% NaCl solution and injected into the tail vein over 10 s using a 27 1/2 g needle. For i.m. injection, 20 mg plasmid DNA was diluted in 100 ml PBS and injected within the thigh muscle of the right leg of the mouse.
Determination of FL protein in sera
The level of FL protein in mice sera was measured by ELISA kit (R&D Systems, Minneapolis, USA) using goat anti-Flt-3 antibody (Santa Cruz, USA). Blood from inoculated mice was collected and allowed to clot at RT for 1 h, followed by further clotting at 41C for 4 h. The sample was then centrifuged at 41C 10 000 r.p.m. for 10 min. The serum obtained was stored at À201C.
Preparation of muscle tissues
Muscle tissues surrounding the injection site were harvested at various days postinjection, homogenized and lysed with Lysis Buffer as described above. The lysate was then subjected to anti-FL ELISA assay.
FACS analysis
Single cell suspension of splenocytes was prepared from mice at day 10 postimmunization, and 5 Â 10 5 cells were stained with FITC-anti-CD11c and PE-anti-IA b (BD Pharmingen, CA, USA) and subjected to FACS analysis.
Quantitation of IFN-g production
Splenocytes isolated from immunized mice were cultured at 5 Â 10 5 cells/well in the presence of MUC-1 or NP-Flu peptide (10 mg/ml) at 371C for 3 days. Culture supernatant was then collected and concentration of IFN-g quantified using anti-mouse IFN-g ELISA kit (BD Pharmingen, CA, USA).
CTL assay
Spleen cells or superficial inguinal lymph node cells harvested from immunized mice were plated at 5 Â 10 5 cells/well and restimulated with synthetic MUC-1 peptide (10 mg/ml) at 371C for 6 days. At day 6, 5 Â 10 3 51 Cr-labeled RMA or RMA-MUC-1 cells were added to the culture. The plates were centrifuged at 100 g for 3 min to initiate cell contact and further incubated for 6 h. Supernatant was harvested and the amount of radioactivity was quantified.
Determination of CTLp frequency
A minimum of 32 replicates, including at least six responder doses (ranging from 1 Â 10 3 to 5 Â 10 5 responder cells per well), was cultured in 96-well plates for 6 days. g-Irradiated C57BL/6 splenocytes (5 Â 10 5 cells) were added as APC, in RPMI 1640 complete medium supplemented with 10 mg/ml synthetic MUC-1 peptide and 2% culture supernatant obtained from Concavalin A linear relationship could be obtained between the dose of responder cells and the frequency of negative wells on a logarithmic scale. The CTLp frequencies were then determined as the inverse of the responder cell dose required for the generation of 37% wells negative for CTL activity. 48 Quantitation of anti-MUC-1 antibody by ELISA Plates were precoated with the MUC-1 peptide (10 mg/ ml) and 2% bovine serum albumin and 50 ml sera obtained from immunized mice were added to the wells at varying dilutions for 1 h at RT. Sheep anti-mouse immunoglobulin-HRP (Amersham Life Science, Uppsala, Sweden) was added and further incubated at RT for an hour. The assays were developed with 50 ml of 0.03% 2,2 0 -azino-di-3-ethylbenzthiazoline sulphonate (Sigma Chemical Co, St Louis, USA), 0.02% H 2 O 2 (Merck, Darmstadt, Germany) in 0.1 M citrate buffer, pH 4.25 for 20-30 min at RT and absorbance at 405 nm determined using an ELISA plate reader. Normal mouse serum (NMS) was employed as the negative control.
Immunohistochemistry of muscle sections
Mice were immunized twice at 10-day intervals. Muscle tissues surrounding the inoculation sites were harvested on day 3 post second immunization and flash frozen in nitrogen-cooled isopentane and sectioned. Serial 10 mmthick frozen muscle sections were adhered to poly-Llysine-coated slides (Sigma Diagnostic, St Louis, USA) and fixed in ice-cold acetone. The muscle sections were then incubated with 0.3% H 2 O 2 in PBS for 80 min and washed with PBS, followed by blocking with 10% goat serum in PBS for 1 h. Sections were incubated with specific primary antibodies at RT for 2 h. Secondary antibodies were added, followed by streptavidin-peroxidase (BD Pharmingen, CA, USA). The reaction was developed using 3,3 0 -diaminobenzidine (DAKO, CA, USA). Muscle sections were also stained with Harris Hematoxylin (Sigma, CA, USA) for nucleus visualization. Primary antibodies used: hamster anti-mouse CD11c and anti-mouse CD3 antibodies (10 mg/ml) (e-Biosciences, CA, USA) and rat anti-mouse CD8a (BD Pharmingen, CA, USA).
Tumour protection assay
Â 10
5 RMA-MUC-1 or RMA parental cells suspended in 200 ml serum-free RPMI media were injected subcutaneously into groups of X5 mice. Mice receiving pNGVLhFLex plasmid DNA inoculation served as the control group. Tumour size is the product of two perpendicular diameters.
